CTLA-4 can function as a negative regulator of T cell activation
- PMID: 7882171
- DOI: 10.1016/1074-7613(94)90071-x
CTLA-4 can function as a negative regulator of T cell activation
Abstract
CD28 and CTLA-4 are related glycoproteins found on T cells. Ligation of CD28 following antigen receptor engagement provides a costimulatory signal required for T cell activation. Anti-CTLA-4 antibodies were generated to examine the role of the CTLA-4 receptor on murine T cells. Expression of CTLA-4 as a homodimer is up-regulated 2-3 days following T cell activation. Anti-CTLA-4 antibodies and Fab fragments augmented T cell proliferation in an allogeneic MLR. However, when optimal costimulation and Fc cross-linking were present, anti-CTLA-4 Mabs inhibited T cell proliferation. Together, these results suggest that the MAb may obstruct the interaction of CTLA-4 with its natural ligand and block a negative signal, or directly signal T cells to down-regulate immune function.
Similar articles
-
CTLA-4 ligation blocks CD28-dependent T cell activation.J Exp Med. 1996 Jun 1;183(6):2541-50. doi: 10.1084/jem.183.6.2541. J Exp Med. 1996. PMID: 8676075 Free PMC article.
-
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.J Immunol. 2000 Aug 1;165(3):1352-6. doi: 10.4049/jimmunol.165.3.1352. J Immunol. 2000. PMID: 10903737
-
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.J Exp Med. 1992 Dec 1;176(6):1595-604. doi: 10.1084/jem.176.6.1595. J Exp Med. 1992. PMID: 1334116 Free PMC article.
-
Expression and functional significance of CTLA-4, a negative regulator of T cell activation.Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11266089 Review.
-
Development and applications of surface-linked single chain antibodies against T-cell antigens.J Immunol Methods. 2001 Feb 1;248(1-2):77-90. doi: 10.1016/s0022-1759(00)00344-6. J Immunol Methods. 2001. PMID: 11223070 Review.
Cited by
-
Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors.J Mol Biol. 2020 Nov 6;432(22):5938-5950. doi: 10.1016/j.jmb.2020.09.013. Epub 2020 Oct 5. J Mol Biol. 2020. PMID: 32976909 Free PMC article.
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
-
B7-1/B7-2 blockade overrides the activation of protective CD8 T cells stimulated in the absence of Foxp3+ regulatory T cells.J Leukoc Biol. 2013 Aug;94(2):367-76. doi: 10.1189/jlb.0313118. Epub 2013 Jun 6. J Leukoc Biol. 2013. PMID: 23744647 Free PMC article.
-
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.Nat Commun. 2024 Aug 27;15(1):7388. doi: 10.1038/s41467-024-51442-2. Nat Commun. 2024. PMID: 39191755 Free PMC article. Clinical Trial.
-
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. Cell. 2015. PMID: 25860605 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous